CRISPR Therapeutics AG
CRSP- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001674416
In the last 90 days, CRISPR Therapeutics AG insiders filed 0 open-market purchases and 2 sales; 525 institutions reported holding it in 13F filings for Q2 2026, worth $5.47B in total; ARK Invest is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.41M in total
- 2
- 13F holdersQ2 2026, +35 vs. previous quarter
- 525
- 13F valueReported value at the end of Q2 2026
- $5.47B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding CRSP, Q2 2026
1 superinvestor reports holding CRISPR Therapeutics AG on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by CRISPR Therapeutics AG insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)5:35 PM ET | Sep 22 | 2 days | Kasinger James R.General Counsel and Secretary | SSale | −10.4K | $60.24 | −$626.5K | −9.9%94.8K after | 10b5-1 |
| Sep 21, 2026 (view filing)6:40 PM ET | Sep 17 | 4 days | Behbahani AliDirector | SSale | −13.7K | $57.09 | −$780.9K | −45.1%16.6K after | |
| Jun 1, 2026 (view filing) | May 29 | 3 days | Patel NaimishChief Medical Officer | SSale | −3.79K | $55.62 | −$210.6K | −16.4%19.4K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Kasinger James R.General Counsel and Secretary | SSale | −3.18K | $46.78 | −$148.9K | −3.3%94.3K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −10.0K | $46.78 | −$468.7K | −3.8%255.5K after | |
| Mar 24, 2026 (view filing) | Mar 23 | 1 day | Prasad RajuChief Financial Officer | SSale | −3.71K | $46.78 | −$173.5K | −19.2%15.6K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Patel NaimishChief Medical Officer | SSale | −3.15K | $48.26 | −$152.0K | −19.3%13.1K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Prasad RajuChief Financial Officer | SSale | −9.87K | $48.26 | −$476.3K | −41.7%13.8K after | 2 lots |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Kasinger James R.General Counsel and Secretary | SSale | −3.45K | $48.26 | −$166.5K | −3.6%91.2K after | |
| Mar 17, 2026 (view filing) | Mar 16 | 1 day | Kulkarni SamarthChief Executive Officer | SSale | −10.3K | $48.26 | −$499.4K | −4.0%245.8K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in CRISPR Therapeutics AG at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Banque Cantonale Vaudoise | 24,065 | $1.31B | 0.18% | +6,602+37.8% | Added |
| ARK Investment Management LLCSuperinvestorARK Invest | 9,460,939 | $516.0M | 3.35% | −1,852,684−16.4% | Reduced |
| BlackRock, Inc. | 8,348,977 | $455.4M | 0.01% | +668,904+8.7% | Added |
| Orbis Allan Gray Ltd | 5,449,161 | $297.2M | 1.02% | −656,850−10.8% | Reduced |
| Capital World Investors | 4,749,525 | $259.0M | 0.03% | +24,488+0.5% | Added |
| State Street Corp | 4,321,666 | $235.7M | 0.01% | +339,166+8.5% | Added |
| GSK plc | 3,220,627 | $175.7M | 29.17% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 2,509,915 | $136.9M | 0.01% | +132,751+5.6% | Added |
| T. Rowe Price Investment Management, Inc. | 2,053,017 | $112.0M | 0.07% | −899,578−30.5% | Reduced |
| Sr One Capital Management, LP | 2,038,763 | $111.2M | 10.70% | 00.0% | Unchanged |